STMicroelectronics NV Rating Reiterated by BNP Paribas (STM)

STMicroelectronics NV (EPA: STM)‘s stock had its “outperform” rating reiterated by equities research analysts at BNP Paribas in a research note issued to investors on Monday, Analyst Ratings Network.com reports. They currently have a €8.69 ($11.29) price target on the stock.

STMicroelectronics NV (EPA: STM) traded up 4.48% on Monday, hitting €7.47. STMicroelectronics NV has a 52-week low of €3.683 and a 52-week high of €7.689. The stock’s 50-day moving average is currently €4.5. The company’s market cap is €6.633 billion.

STM has been the subject of a number of other recent research reports. Analysts at AlphaValue reiterated a “buy” rating on shares of STMicroelectronics NV in a research note to investors on Thursday, May 23rd. They now have a €9.45 ($12.27) price target on the stock. Separately, analysts at JPMorgan Chase reiterated an “overweight” rating on shares of STMicroelectronics NV in a research note to investors on Monday, May 20th. They now have a €8.80 ($11.43) price target on the stock. Finally, analysts at Grupo Santander reiterated an “underweight” rating on shares of STMicroelectronics NV in a research note to investors on Friday, May 17th. They now have a €5.20 ($6.75) price target on the stock.

One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. STMicroelectronics NV has a consensus rating of “Buy” and an average price target of €7.24 ($9.41).

STMicroelectronics N.V. is a global independent semiconductor company that designs, develops, manufactures and markets a range of semiconductor products used in a variety of microelectronic applications, including automotive products, computer peripherals, telecommunications systems, consumer products, industrial automation and control systems.

Latest News

Somewhat Positive Media Coverage Somewhat Unlikely to Impact Gemphire Therapeutics  Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Gemphire Therapeutics Stock Price
Aviat Networks  Given Daily Media Impact Rating of 0.09
Aviat Networks Given Daily Media Impact Rating of 0.09
Papa Murphy’s  Getting Somewhat Positive News Coverage, Report Shows
Papa Murphy’s Getting Somewhat Positive News Coverage, Report Shows
EXFO  Given Average Recommendation of “Hold” by Brokerages
EXFO Given Average Recommendation of “Hold” by Brokerages
Brokerages Set ANI Pharmaceuticals Inc Common Stock  Price Target at $79.00
Brokerages Set ANI Pharmaceuticals Inc Common Stock Price Target at $79.00
MediBloc [QRC20] Price Tops $0.0061 on Top Exchanges
MediBloc [QRC20] Price Tops $0.0061 on Top Exchanges


© 2006-2018 Ticker Report. Google+.